EEF2K and neoplasm: Tumour growth was measured on alternate days, showing that knockdown of EEF2K reduced the tumour growth by up to 65%, in a manner similar to cells in which BRAF had been targeted and compared to the siScramble control (Figure 6A, p < 0.0001).